Press kit

A selection of the Owkin team

Boilerplate

Owkin is building the first universal AI co-pilot called K to lay the foundation for Biological Artificial Superintelligence (BASI). This co-pilot integrates a suite of AI agents that decode complex biology, accelerate research, and dramatically increase productivity. Acting as copilots, Owkin K agents will automate drug discovery and diagnostics and power next-generation pharma companies.

Owkin K will be powered by the world’s largest federated multimodal patient data network, a robotized lab, leading AGI technologies, and cutting-edge multimodal foundation models and LLMs.

Media contact

Owkin’s experts are available to comment on topics related to medical research and Al.

For international media requests, please contact stephanie.libous@owkin.com

For French media requests, please contact malika.labou-ext@owkin.com

About our founder

Thomas Clozel M.D.
Chief Executive Officer and co-founder

Thomas leads Owkin as CEO. He is a former Assistant Professor of Clinical Onco-Hematology at Hopital Henri Mondor in Paris and former member of Ari Melnick’s lab at the Weill Cornell Medical College. He ensures that patient health is prioritized when developing breakthrough medical technologies, bringing a patient-centric approach to each Owkin project.

FAQs

Where is Owkin based?
Close
What is Owkin's founding story?
Close
What makes Owkin different?
Close
How does Owkin ensure data privacy and security?
Close
How much investment has Owkin received?
Close